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Background: The soluble cell adhesion molecules and adipokines are elevated in patients with obesity,
hypertension, type 2 diabetes mellitus, breast cancer and atherosclerosis.
Objective: To investigate the relationship between anthropometric profile, dietary intake, lipid profile and fasting
glycemia with serum levels of adipokines (adiponectin and PAI-1) and adhesion molecules (ICAM-1 and VCAM-1) in
women without breast cancer undergoing routine mammographic screening.
Design: Transversal study.
Subjects: One hundred and forty-five women over 40-years old participated in this study.
Results: In 39.3% of cases the BMI was above 30 kg/m2; 46.9% had hypertension, 14.5% had type 2 Diabetes
Mellitus, 31.7% had dyslipidemia and 88.3% presented a waist-to-hip ratio ≥ 0.8. A linear correlation was found
between serum levels of PAI-1 and triglycerides, between serum levels of PAI-1 and WHR and between serum levels
of VCAM-1 and BMI.
Conclusion: We found a high prevalence of obesity and metabolic syndrome. PAI-1 and VCAM-1 levels were
correlated with clinical indicators of obesity and overweight.
Keywords: Obesity, Adiponectin, Plasminogen Activator Inhibitor type-1, Vascular Cell Adhesion Molecule-1,
Intercellular Adhesion Molecule-1Background
Forty-nine percent of the Brazilian adult population is
overweight and 14.8% is obese [1]. The southern region
of the country concentrates the highest percentage of
overweight and obesity among women (51.6% and
19.6%, respectively) [2,3]. Obesity has been identified as
a risk factor for breast carcinoma in postmenopausal
women and is associated with worse prognosis [4]. Adi-
pose tissue is an important source of peripheral conver-
sion of estrogen via the aromatase enzyme, which may
induce mitogenic activity on mammary epithelium. The* Correspondence: dornellesrosa@hotmail.com
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distribution, and reproduction in any mediumassociation between obesity and insulin resistance is well
established and there is evidence that insulin and
insulin-like growth factors are involved in the develop-
ment of breast cancer [4].
Obesity alters the expression of adipokines , which are
cytokines secreted by the adipose tissue [5,6]. The adipo-
kine adiponectin (acrp30, adipoQ, apM1 gene product)
seems to exert a potent anti-inflammatory and vascular
protective effect. Reduced levels of adiponectin have
been implicated in the pathogenesis of obesity, type 2
diabetes mellitus and breast cancer in postmenopausal
women [6-10].
Plasminogen activator inhibitor type-1 (PAI-1) is an-
other adipokine that has been used as biomarker of the
interactions between the fibrinolytic system, inflammation,d Central Ltd. This is an Open Access article distributed under the terms of the
/creativecommons.org/licenses/by/2.0), which permits unrestricted use,
, provided the original work is properly cited.
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and atherosclerotic diseases [11,12]. It has also a relevant
role in tumoral adhesion, cellular migration and angiogen-
esis. Elevated levels of PAI-1 seem to be associated with
worse prognosis in breast cancer [13].
The soluble cell adhesion molecules are elevated in
patients with obesity, hypertension, type 2 diabetes mel-
litus and atherosclerosis [14-16]. Elevated levels of the
intercellular adhesion molecule-1 (ICAM-1) and vascu-
lar cell adhesion molecule-1 (VCAM-1) are found in
stage IV breast cancer patients and are associated with
worse prognosis [17].
This study aimed to investigate the relationship be-
tween anthropometric profile (body mass index and
waist-to-hip ratio), food intake frequency, lipid profile
and fasting glycemia with serum levels of adipokines
(adiponectin and PAI-1) and adhesion molecules
(ICAM-1 and VCAM-1) in a subgroup of women
derived from a cohort of 10,000 women undergoing an-
nual mammographic screening in Southern Brazil
(Núcleo Mama Porto Alegre - NMPOA). The NMPOA
is a public-private research project funded by the Asso-
ciação Hospitalar Moinhos de Vento in partnership with
the Porto Alegre City Health Department, which aims to
reduce by 20% the incidence of breast cancer in the city.




A consecutive and unselected sample of 145 women
without breast cancer (age over 40 years) enrolled in a
mammography screening program in the city of Porto
Alegre (Núcleo Mama Porto Alegre – NMPOA cohort)
was recruited for this study during routine mammo-
graphic visits between January and April 2009. Study ap-
proval was obtained from the ethics committees of the
participating institutions (Hospital Moinhos de Vento
number 2009/44 and Hospital de Clínicas de Porto Ale-
gre number 08–649) and all individuals recruited for the
study signed an informed consent form. Demographic
and clinical information as well as results from mammo-
graphic screening were obtained from chart review.
Blood collection and analysis of adipokines, PAI-1, ICAM-1
and VCAM-1
Peripheral blood samples were obtained after a 12h fast-
ing period by venipuncture of the antecubital vein. All
samples were centrifuged at 3000 rpm for 10 minutes,
and serum was aliquoted and stored at - 80°C. Serum
levels of adipokines (Apn and PAI-1) and adhesion
molecules (ICAM-1 and VCAM-1) were analyzed by the
multiplex immunoassay method in an automatic equip-
ment LuminexW 200™ IS (Luminex Corporation, Austin,Texas, USA), using the commercial kit ‘Human cardio-
vascular disease (CDV) panel 1 LINCOplex’ (LINCO Re-
search, EUA) for simultaneous measurements of Apn,
PAI-1, ICAM-1, VCAM-1. For the analysis, samples
were thawed, centrifuged at 3000 rpm for 10min and
diluted in the appropriate sample matrix in 1:400,
according to the kit instructions. The intra- and inter-
analysis variations of the biomarkers were 9.2% and
15.9% for adiponectin, 11.8% and 12.5% for PAI-1, 7.9%
and 9.7% for ICAM-1 and 4.5% and 8.5% for VCAM-1,
respectively.
Anthropometric measures and dietary intake
Anthropometric measures (weight, height, waist circum-
ference and hip circumference) were measured according
to the recommendations of the Brazilian Ministry of
Health [19,20]. Body mass index (BMI) was calculated by
dividing weight in kilograms (kg) by height in square
meters (m2) and categorized according to the World
Health Organization (WHO) criteria [20]. The waist-to-
hip ratio (WHR) was established by dividing the value of
the waist circumference by the hip circumference. For
women, values ≥0.8 are accepted as a risk factor for com-
plications related to obesity [19]. Body weight was mea-
sured on a digital platform scale with a capacity of 150kg.
Height was measured with a 2m stadiometer attached to
the scale, with patients barefoot and wearing as little
clothing as possible. Circumferences were measured with
a standard inelastic and flexible tape. The entire NMPOA
cohort study was described in 2009 [2].
The dietary pattern of the participants was character-
ized by a food frequency questionnaire (FFQ) applied at
the time of blood collection. The FFQ consisted of 103
items designed to ascertain in detail the quantities and
kinds of foods consumed over the previous year [1].
Study subjects were asked to report their frequency of
consumption (by day, week, month, or year) and portion
size of each food item consumed, over the one-year
period preceding confirmation of disease. The food
groups included in the FFQ were vegetables (carrots,
onion, lettuce, tomatoes), potatoes, fruit, cereals (categor-
ies of bread, pasta, rice, and pizza), meat and meat pro-
ducts, fish, dairy products (categories of cheese, milk,
and yogurt), eggs, cakes, linseed, beans, added fat, added
sugar and alcoholic beverages. Data on dietary intake
were evaluated with the DietWinW software and classified
according to the Brazilian Table of Nutrition (BTN) [1].
Statistical analysis
A descriptive analysis of all variables was performed for
the quantitative variables, using the mean and standard
deviation. The categorical clinical variables were
expressed as proportions. Student’s t-test was used to
compare means. Pearson’s correlation coefficient was
Table 2 Values of Adiponectin PAI-1, VCAM-1 and ICAM-1
Variables (ng/ml) Mean values (± SD)
Adiponectin 279.4 (±61.3)
PAI-1 90.31 (±37.9)
ICAM −1 56.9 (±39.2)
VCAM-1 321 (±60.8)
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numerical variables. When there was a linear trend,
means were compared using the ANOVA test. We used
multivariate analysis to control for confounding vari-
ables, using p <0.1 for selecting covariates for the model.
The statistical analysis was performed using SPSS ver-
sion 17.0 (Statistical Package for Social Science, SPSS
Inc, Illinois, EUA). The significance level adopted was
p<0.05.Results
Population sample
The overall clinical, anthropometric and dietary charac-
teristics of the sample are described in Table 1.Table 1 Characteristics of the sample (n=145)
Variables Values (± SD)
Mean age (years) 55.74 (±8,01)
Mean BMI (kg/m2) 29.46 (±5,6)
Mean WHR 0.88 (±0,06)




Mean age of menopause (years) 46 (±5.6)
Postmenopausal status (%) 64.5
Mean number of meals/day 3.94 (±1)
Mean energy intake (kcal/day) 2107 (±599)
Mean fasting glycemia levels (mg/dl) 105.38 (±26.9)
Mean triglycerides levels (mg/dl) 165.63 (±99)
Mean total cholesterol levels (mg/dl) 205 (±44)
Mean HDL cholesterol levels (mg/dl) 53.48 (±15.5)
Mean LDL cholesterol levels (mg/dl) 115.7 (±40.5)
Prevalence of diabetes (%) 14.5
Prevalence of hypertension (%) 46.9
Prevalence of dyslipidemia (%) 31.7
Use of oral hypoglycemic agents (%) 6.9
Use of statins (%) 12.4








BMI – body mass index; WHR - waist-hip ratio; HDL-High Density Lipoprotein;
LDL-Low Density Lipoprotein.
* Defined as a minimum of 30 minutes of exercises 2 times a week.Serum biomarkers
Serum levels of Adiponectin, PAI-1, VCAM-1 and
ICAM-1 in the sample are described in Table 2.
Association of dietary intake and correlation between
energy and serum levels of adipokines and adhesion
molecules
Food consumption was dichotomized by number of
meals (up to 4 and more than 4) (Table 3). No associ-
ation was found between dietary intake and amount of
calories/day ingested with serum levels of adipokines
and adhesion molecules.
Correlation between lipid profile, blood glucose and
levels of serum adipokines and adhesion molecules
Analysis of total cholesterol, LDL, HDL, triglyceride and
glucose and their relationship to serum levels of adipo-
nectin, PAI-1, ICAM-1 and VCAM-1 showed a linear
correlation between serum levels of PAI-1 and triglycer-
ides (r2=0.07, β = 0.083; p=0.001) (Table 4). This means
that for every 10ng/ml increase of triglycerides, there
was an increase of 0.8ng/ml in the PAI-1 serum level,
Correlation between BMI and serum levels of adipokines
and VCAM-1
There was an inverse correlation between VCAM-1
serum levels and BMI (r2=−0.22; β=−1.77; p= 0.007).
(Table 5). For every 1 kg/m2 increase in BMI, there was
a reduction of 1.7ng/ml in the VCAM-1 serum level.
Correlation between waist-to-hip ratio (WHR) and serum
levels of adipokines and VCAM-1
There was a linear correlation between PAI-1 serum
levels and WHR (r2=0.16; β = 108.07; p= 0.04) (Table 5).
For an increase of 0.1 units of WHR there was an in-
crease of 10.8ng/ml of PAI-1 levels.Table 3 Dietary intake, energy correlation (kcal/day) and
serum levels of adiponectin, PAI-1, ICAM-1 e VCAM-1
Variables Association with dietary intake Energy correlation
p-value rs p-value
Adiponectin 0.9 0.8 0.31
PAI-1 0.2 −0.01 0.82
ICAM-1 0.7 0.01 0.99
VCAM-1 0.7 −0.05 0.95
Table 4 Correlation of serum levels of adipokines, cell adhesion molecules and metabolic variables
Variables Adiponectin PAI-1 ICAM-1 VCAM-1
rs p-value rs p-value rs p-value rs p-value
Total cholesterol −0.02 0.79 0.05 0.47 −0.05 0.51 −0.1 0.2
HDL cholesterol 0.05 0.48 0.07 0.37 −0.05 0.51 −0.02 0.8
LDL cholesterol −0.03 0.7 −0.05 −0.5 −0.01 0.21 −0.04 0.57
Triglycerides −0.01 0.8 0.26 0.001 0.05 0.5 −0.007 0.9
Fasting glucose 0.07 0.34 0.05 0.48 0.01 0.87 0.1 0.19
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As part of a cohort study of 10,000 woman for the pre-
vention of breast cancer in Porto Alegre, Southern
Brazil, the present study has found alarming results, with
39.3% of obesity and 37.2% of overweight among our
study population, which was recruited consecutively
from the main cohort. In addition, we encountered a sig-
nificant percentage of women with type 2 diabetes melli-
tus, hypertension, dyslipidemia and high WHR. One
possible explanation for the high prevalence of over-
weight in our sample may be the low level of education,
as 60% of women had completed just elementary educa-
tion [21]. The relationship between education and obes-
ity has been described in other studies, as the one
carried out with the Danish population, which con-
cluded that education was consistently associated with
BMI and obesity [22]. Another explanation for the high
prevalence of overweight and obesity could be the lower
rate of physical activity, since only 35% of the partici-
pants were performing exercises on a regular basis.
We found a positive correlation between serum levels
of PAI-1 and serum triglycerides. PAI-1 levels correlate
significantly with a variety of adiposity measures (BMI,
waist circumference, WHR, total fat, visceral adipose tis-
sue), and also with markers of the metabolic syndrome
(inflammatory markers, insulin, glucose, triglycerides
and high density lipoprotein) [23]. The activity of PAI-1
is associated with insulin resistance, regardless of serum
triglycerides and other potential confounding factors
[24-27]. Thus, our findings reinforce the relationship of
this adipokine with obesity, especially with abdominal
obesity [26-29].
There was also a positive correlation between serum
levels of PAI-1 and WHR. It was demonstrated that theTable 5 Association of BMI and WHR with serum levels of
adiponectin, PAI-1, ICAM-1 and VCAM-1
Variables Association with BMI Association with WHR
rs p-value rs p-value
Adiponectin 0.04 0.58 −0.04 0.62
PAI-1 0.08 0.30 0.16 0.04
ICAM-1 0.05 0.52 0.05 0.49
VCAM-1 −0.22 0.007 −0.02 0.76increase of visceral adipose tissue (VAT) is directly asso-
ciated with levels of PAI-1, even after adjusting for BMI
[30]. Excess of adipose tissue increases the production of
PAI-1, leading to an impairment of the fibrinolytic sys-
tem [30]. PAI-1 concentration varies according to race,
ethnicity and gender, although differences in body com-
position and in the distribution of adipose tissue may be
responsible for much of this variability [31].
We showed an inverse correlation between BMI and
serum levels of VCAM-1. Although obesity is associated
with an increase rather than a decrease in cell adhesion
molecules expression, including VCAM-1 [32], the
mechanisms that explain the pathophysiological changes
which make obesity a risk factor for atherosclerotic dis-
eases, and therefore increase the adhesion molecules, are
not yet fully understood. The results of the studies are in
fact controversial [33-35].
A study found that elevated levels of VCAM-1 in non-
obese patients with polycystic ovary syndrome was asso-
ciated with insulin resistance, independent of the BMI
[36]. We did not measure insulin levels and neither eval-
uated homeostasis model assessment of insulin resist-
ance index (HOMA IR), which could be helpful in
establishing the presence of metabolic syndrome, what
could explain variations in VCAM-1 levels.
Adhesion molecules are associated to breast cancer
and was shown to be reduced after breast cancer therapy
[17], leading to the point that obesity and metabolic
syndrome-type characteristics may possibly increase the
likelihood of cancer risk. Therefore, there may be signifi-
cant differences in ICAM and VCAM in patients with
and without breast cancer (regardless of obesity and
metabolic syndrome) and this should be investigated in
future studies.
Since most women in this study were overweight and
had increased WHR we would expect to find a correl-
ation of BMI and WHR with ICAM-1. However, this
correlation was not found. The serum levels of ICAM-1
are positively correlated with obesity, in particular, to
visceral adipose tissue [37]. On the other hand, it was
demonstrated that serum levels of ICAM-1 decreases
after weight reduction [38]. Since no data was collected
on weight modification, we could not evaluate this
association.
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between serum levels of adiponectin and the variables
associated to overweight and obesity. According to the
literature, serum levels of adiponectin are negatively cor-
related with BMI in male and female individuals as well
as with visceral fat [39]. Patients with type 2 diabetes
mellitus, hypertension, and breast cancer, for example, also
show reduced peripheral levels of adiponectins [40-42].
Biological variations of adiponectin serum concentrations
seem to be associated with differences in gender, age and
race [43]. Women have 35% higher plasma adiponectin
than male individuals [44]. A possible explanation for this
profile is that androgens may reduce the concentrations of
this biomarker in men [43,44].
It seems that the ratio adiponectin:leptin may be more
important than the measure of the absolute level of
these biomarkers. Recent studies have shown that the
adiponectin:leptin ratio is reduced in women with breast
cancer, and that BMI presents a negative and a positive
correlation, respectively, with serum levels of adiponec-
tin and leptin [45,46].
Conclusion
In conclusion, we found a higher prevalence than
expected of overweight and obesity in women undergo-
ing mammographic screening in Southern Brazil. PAI-1
levels were correlated to lipid and anthropometric pro-
file and VCAM-1 was inversely related to BMI. Add-
itional studies are necessary to determine if adipokines
and adhesion molecules are indeed associated with an
increased risk for diseases like type 2 diabetes mellitus,
hypertension and breast cancer.
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